Skip to main content
德源药业 logo

德源药业 — Investor Relations & Filings

Ticker · 920735 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2025-03-30 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920735

About 德源药业

http://www.pharmdy.com

Deyuan Pharmaceutical specializes in the research, development, production, and commercialization of therapeutic drug preparations. The company focuses on chronic disease management, particularly in the fields of endocrinology and cardiovascular health. Its core product line includes treatments for diabetes, hypertension, and hyperlipidemia, featuring medications such as Metformin Hydrochloride sustained-release tablets, Pioglitazone Hydrochloride, and Valsartan. The organization emphasizes technological innovation and maintains rigorous quality control standards across its manufacturing processes. By leveraging advanced formulation technologies, the company develops high-efficacy pharmaceutical solutions aimed at addressing the long-term needs of patients with metabolic and circulatory disorders.

Recent filings

Filing Released Lang Actions
关于以自有闲置资金进行委托理财的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding the use of idle funds for entrusted financial management. It details the purpose, amount, method, duration, decision-making process, risk analysis, and impact on the company. The document includes board meeting resolutions approving the proposal and mentions compliance with disclosure obligations. The content focuses on financing activities related to the company's capital management rather than financial results or audit information. The document length is 1423 characters, which is relatively short but contains substantive information about financing decisions, not just a notice of report publication. Therefore, it fits best under Capital/Financing Update (CAP).
2025-03-30 Chinese
关于自动化立体库及综合车间建设工程、1104车间建设改造工程项目立项的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding the approval and details of new construction and renovation projects for an automated warehouse and production workshops. It includes project descriptions, investment amounts, funding sources, and board meeting approvals. There is no financial data, earnings information, or regulatory filings related to financial results. The document is a formal announcement of a capital investment project requiring shareholder approval, which fits the category of Capital/Financing Update (CAP). The document length is short (2108 characters), and it is not a report publication announcement or certification. Therefore, the best classification is CAP with high confidence.
2025-03-30 Chinese
内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It includes an audit opinion on the effectiveness of internal controls over financial reporting as of December 31, 2024. The document is issued by a registered accounting firm and references auditing standards and internal control guidelines. It is a standalone audit report focused on internal control effectiveness, not a full annual report or interim financial report. The length is short (1239 characters), but the content is substantive and specific to an audit report on internal controls. Therefore, it fits the category of Audit Report / Information (AR). FY 2024
2025-03-30 Chinese
2024年年度独立董事述职报告（周建平）
Board/Management Information Classification · 95% confidence The document is titled as the "2024 Annual Independent Director's Report" from Jiangsu Deyuan Pharmaceutical Co., Ltd. It is a detailed report by an independent director summarizing their duties, attendance at board meetings, opinions on company matters, communication with auditors, and overall evaluation of the company's governance and operations during the 2024 fiscal year. The content focuses on the independent director's role, oversight, and compliance with regulations, rather than financial statements or audit results alone. This type of document is a report on board/management information, specifically the independent director's annual statement on their duties and observations. It is not an annual report (10-K), audit report (AR), or a simple announcement. The document length (4773 characters) and detailed content confirm it is a substantive report rather than a brief announcement or certification. Therefore, the most appropriate classification is Board/Management Information (MANG).
2025-03-30 Chinese
关于2024年内部控制自我评价报告的公告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Self-Evaluation Report" for the year 2024 by Jiangsu Deyuan Pharmaceutical Co., Ltd. It contains detailed descriptions of the company's internal control environment, risk assessments, control activities, information and communication, and internal supervision. It also includes evaluation conclusions about the effectiveness of internal controls, absence of major defects, and compliance with relevant laws and regulations. The document is comprehensive, with over 14,000 characters, and contains substantive content about internal control evaluation rather than just an announcement or certification. This type of report aligns with the category of Audit Report / Information (AR), which includes standalone audit reports and internal control evaluations, excluding full annual reports. It is not an Annual Report (10-K) because it focuses solely on internal control evaluation and does not present full financial performance or company activity. It is not a Regulatory Filing (RNS) because it contains detailed substantive content rather than a brief compliance or certification document. Therefore, the appropriate classification is AR (Audit Report / Information). FY 2024
2025-03-30 Chinese
关于召开2024年年度股东大会通知公告（提供网络投票）
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2024 Annual General Meeting (AGM) of Jiangsu Deyuan Pharmaceutical Co., Ltd. It includes information about the meeting date, voting methods (including online voting), agenda items to be discussed at the AGM such as the 2024 annual board report, supervisory board report, independent directors' reports, financial reports, profit distribution proposals, appointment of accounting firms, capital increase, and amendments to the company charter. It also provides procedural details for shareholders to attend and vote, including registration methods and contact information. The document does not contain the actual annual report or financial statements but rather the announcement and details of the AGM itself. The length is about 4934 characters, which is consistent with a detailed AGM notice. Therefore, this document fits the category of AGM Information (AGM-R).
2025-03-30 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.